TPI AND STERLING TO BRING INCREASED COMPETITION IN THE UK CODEINE MARKET

Statement by TPI Enterprises Ltd. (TPE) CEO, Jarrod Ritchie
(ASX : TPE)

Melbourne, Australia, 17 November 2016

TPI Enterprises Ltd (TPE) and Sterling Pharma Solutions Ltd (SPSL) of the UK are pleased to announce they have entered into an exclusive toll processing agreement to manufacture and sell Codeine Phosphate (CPO) in the UK market.

The UK market for CPO is one of the largest in the world, valued at around AUD 40 million per annum.

The agreement between TPE and SPSL allows TPE to participate in the UK market providing it access to a new, significant and from a regulatory basis, previously inaccessible customer base.

The key input for CPO production is the narcotic raw material made by TPE at its site in Victoria. This agreement provides TPE with the means to leverage its unique low cost production advantage to expand its market share in a country that has traditionally high product demand, but very limited supply options.

SPSL will manufacture the CPO at its Dudley Site near Newcastle.

"We are delighted to be the partner of choice to support TPE during this exciting period of growth", Sterling Pharma CEO, Kevin Cook.

Jarrod Ritchie, TPI Enterprises CEO, "A combination of Sterling's API production capability with TPE's low cost raw material supply will greatly enhance customers' options in the UK Market".

This is the first step in TPE's plan to expand its presence in the UK Market.

For more information contact:

Jarrod Ritchie
Managing Director / CEO
+61 3 9301 0800

Jaime Pinto
Company Secretary
+61 2 9210 7020

About TPI Enterprises Limited

TPI Enterprises Limited (TPI) is one of three licensed poppy processors in Australia, and the only Australian-owned company. It is one of eight processors worldwide producing Narcotic Raw Material for the international pharmaceutical industry. TPI has developed an innovative, efficient and environmentally-sustainable extraction and purification manufacturing process which allows TPI to deliver a highly competitive pricing platform.

About Sterling Pharma Solutions Ltd

Sterling Pharma Solutions Ltd (SPSL) opened in 1969 and provides Contract Development and Manufacturing services. The Dudley site produces clinical trial and commercial quantities of API (Active Pharmaceutical Ingredients) product from grams to tonnes per annum. It has three main plant areas which can perform demanding and hazardous chemistry such as hydrogenation, halogenation, Friedel-Crafts and cyanation. The site is spread over an area of 169,000 sq. metres and is approved by MHRA (Medical Health Regulatory Authority), PMDA and FDA approved.